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Objectives The aim of the present study was to assess the feasibility and safety of target-directed
sampling of right ventricular (RV) endomyocardial biopsies (EMB) in patients with arrhythmogenic
right ventricular cardiomyopathy (ARVC).
Background EMB is an integral part of the diagnostic evaluation of ARVC. Due to safety concerns,
EMB are often obtained from the RV septum, which is usually spared from characteristic alterations.
At our institution, EMB in ARVC patients were sampled target-directed from predilection areas and
areas with abnormal contraction.
Methods Under ﬂuoroscopic guidance, 3,777 EMB samples from 6 different RV sites were obtained
in 482 patients who were evaluated for unclear cardiomyopathy (n  280; 58%), assumed myocardi-
tis (n  59; 12%), or unexplained ventricular tachyarrhythmias (n  143; 30%). Complication rates
were compared with those from exclusively septal EMB procedures (n  2,321) in 271 patients after
heart transplantation (HTx).
Results Overall, no procedure-related deaths or sustained ventricular tachyarrhythmias occurred.
A pericardial effusion was reported in 6 of 161 patients with the ﬁnal diagnosis of ARVC (3.7%)
needing no further intervention in all but 1 patient (0.6%) who required pericardiocentesis. Among
the non-ARVC patients (n  321), the incidence of a minor pericardial effusion (3.9%) and cardiac
tamponade (2.2%) was comparable to that in ARVC (p  NS) but was higher when compared with
Tx (p  0.001). A transient complete atrioventricular block occurred in 1 of 321 non-ARVC (0.3%)
nd 2 of 271 HTx patients (0.1%).
onclusions Multisite target-directed EMB sampling in ARVC is a safe procedure when performed
y experienced interventionalists. The procedure-related complication rates were low and compara-
le to those in other cardiomyopathies. (J Am Coll Cardiol Intv 2011;4:1142–8) © 2011 by the
merican College of Cardiology Foundation
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1143Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an
inheritable disease accounting for ventricular tachyarrhythmias
and sudden cardiac death in a young population (1). Localized
rather than diffuse atrophy, predominantly of the right ventricular
(RV) free wall myocardium, with subsequent replacement by
fibrous and fatty tissue mainly of the RV outflow tract, the right
ventricular apex, and the inflow tract (subtricuspid region) repre-
sent the histopathological hallmarks of ARVC. The RV septum is
usually spared. A left ventricular involvement is frequent but
clinically unapparent until advanced stages of the disease.
Despite the proposed list of major and minor criteria (2),
clinical diagnosis of ARVC in the absence of 1 single
diagnostic test (3) remains a true challenge. In the modified
version of the Task Force criteria, evidence of fibrofatty
replacement on endomyocardial biopsies (EMB) still is
considered as a major criterion (4). Target-directed EMB
sampling from predilection areas of the RV as well as from
areas with regional RV wall motion abnormalities in pa-
tients with ARVC is yet perceived to carry an increased risk
of perforation, given the reduced thickness of the RV free
wall with additional structural alterations due to fibrofatty
replacement and only scarce residual viable myocardium.
However, histological confirmation of ARVC is crucial in
patients with suspected ARVC in whom noninvasive eval-
uation remains inconclusive. Therefore, we analyzed the
procedure-related complications in a large cohort of ARVC
patients who were studied at our institution.
Methods
Study patients. The EMB procedures were performed ac-
cording to current guidelines in patients who were trans-
ferred to our institution for diagnostic evaluation of unclear
cardiomyopathy (n  280; 58%), assumed myocarditis (n 
9; 12%) (Table 1) (5–8), or unexplained ventricular tachy-
rrhythmias (n 143; 30%). Written informed consent was
btained before EMB sampling in all patients.
After careful and detailed investigations, diagnosis of
RVC was made in 161 patients. All non-ARVC patients
ere subsumed under control Group-1 (control-1) (Table 1).
e analyzed the procedure-related in-hospital complica-
ions in this patient cohort and compared the results with
hose that occurred in the course of exclusively septal EMB
rocedures in 271 heart-transplant recipients (HTx) (mean
ge 51  13 years) (Table 1). These patients served as a
econd control group (control-2), because septal EMB in
Tx patients are considered to carry a lower risk of major
omplications (9).
A major EMB-related complication was defined as
eriprocedural death, sustained ventricular tachyarrhyth-
ias (i.e., lasting 30 s or requiring cardioversion for
emodynamic instability), complete atrioventricular (AV)
lock, or pericardiocentesis due to cardiac tamponade.ericardial effusion (PE) with no need for further interven-
ion/treatment was defined as a minor complication.
RV EMB. Right ventricular EMB was performed under
uoroscopic guidance during diagnostic right heart cathe-
erization (5). For femoral vein approach, a 7-F long sheath
96 cm; Cordis, Haan, Germany) was placed in the RV and
1.8  1,000 mm bioptome (Pilling Weck, Karlstein am
hein, Germany) was used for EMB sampling. For jugular
ein approach, an 8-F introducer sheath (11 cm, diameter
.7 mm; Cordis) with a 1.8  510 mm bioptome (Teleflex
edical, Tuttlingen, Germany) was employed. In ARVC
99%) and in control-1 patients (96%), the right femoral
ein was the most commonly used access site, in contrast to
he predominantly internal jugular vein approach in HTx
atients (91%).
To ensure target-directed positioning of the bioptome,
tandard fluoroscopic view angles of 30° right anterior oblique
nd 60° left anterior oblique projection were adjusted for the
MB procedure. The integrated information from all available
maging techniques (cardiac magnetic resonance imaging and
-dimensional transthoracic echo-
ardiography) was used for the
lanning of target-directed RV
iopsy sampling.
Besides continuous electrocar-
iographic recording, right atrial as
ell as RV pressure were recorded
efore and immediately after biopsy
ampling to detect a potentially im-
ending cardiac tamponade. A
ransthoracic 2-dimensional echo-
ardiogram was additionally per-
ormed after the biopsy procedure
nd before discharge.
Technique of RV EMB sampling. The bioptome jaws were
opened just outside the long sheath, and the RV wall was
approached with jaws open to avoid both distension and
perforation of the trabecular system and of the RV free wall
(Fig. 1). The jaws were closed after stable contact with the
RV wall was established; EMB samples were retrieved.
Finally, the bioptome and the long sheath were removed
from the RV. This protocol was developed by our group and
applied in 2 large multicenter, multinational registries and
studies funded by the European Union and the National
Institute of Health (10,11). Biopsies were fixed in pre-
specified media according to the destined further analyses.
These included formalin (histology), glutaraldehyde (elec-
tron microscopy), and liquid nitrogen (molecular biology).
Results of histological semiquantitative analyses of biopsy
specimen were defined as “normal” in case they did not
reveal any pathological alterations, “unspecific” if abnormal
histological findings—such as isolated fatty replacement,
mild interstitial fibrosis, or lymphocytic cell infiltration,
Abbreviations
and Acronyms
ARVC  arrhythmogenic
right ventricular
cardiomyopathy
AV  atrioventricular
EMB  endomyocardial
biopsy
HTx  heart transplantation
PE  pericardial effusion
RV  right ventricle/
ventricularwhich are considered compatible but nonspecific for the
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1144histological diagnosis of ARVC were present—and “indic-
ative” in case histological findings were specific for ARVC
according to current criteria (4).
Statistical analysis. Differences of metric target variables
between groups were assessed by parametric methods (anal-
ysis of variance, Student t test) or nonparametric methods
Kruskal–Wallis test, Mann–Whitney U test) as appropri-
te. In case of binary target variables, the chi-square-test
as used, and p values 0.05 were regarded as significant.
ata are expressed as mean  SD or median (interquartile
range) where applicable (SPSS; version 16.0 for Windows,
SPSS, Inc., Chicago, Illinois).
Results
Patient characteristics. To assess the procedure-related
omplications of multisite target-directed EMB in patients
ith ARVC in relation to the 2 control groups (Table 2),
ajor and minor adverse events were analyzed for the entire
tudy population as well as for different groups according to
he final clinical diagnosis of the patients (Table 1). Among
hese were 161 patients with ARVC (21%) and 271 patients
36%) after HTx (control-2). Control Group-1 comprised
Table 1. Clinical and Procedural Characteristics of S
All Patients
Demographic data
Male 753 (68)
Age, yrs 46 15
EMB sampling
EMB procedures 2,803 (100)
Total RV biopsy samples 14,258 (100) 1
Number of RV biopsy samples/patient 5 (4–8)
Nonseptal sites for EMB sampling 0 (0–2)
Complications/procedure
Death 0
Sustained ventricular tachyarrhythmias 0
Complete AV block 3 (0.1)
Total PE 36 (1.3)
Major PE† 8 (0.3)
Minor PE‡ 28 (1.0)
Complications/RV biopsy samples
Death 0
Sustained ventricular tachyarrhythmias 0
Complete AV block 3 (0.02)
Total PE 36 (0.2)
Major PE† 8 (0.06)
Minor PE‡ 28 (0.2)
Values are n (%), mean  SD, or median (interquartile range). *Subg
versus right ventricular (RV) diseases/cardiomyopathy (CMP) (Control
‡Requiring no further intervention/treatment.
AV atrioventricular; EMB endomyocardial biopsy sampling; HT21 patients (43%), including 108 patients with dilativeardiomyopathy (34%), 11 patients with hypertrophic car-
iomyopathy (3%), 59 patients with acute suspected or
onfirmed myocarditis (18%), 48 patients with Brugada
yndrome (15%), 6 patients with long QT syndrome (2%),
9 patients with idiopathic ventricular fibrillation (6%), and
0 patients with RV outflow tract (22%).
In the overall cohort of 2,803 procedures, 51% of proce-
ures (n  2,119) were performed by 7 interventionalists
ith experience of more than 100 RV EMB procedures
range n  111 to 442). Interventionalists with experience
of more than 25 RV biopsy procedures (range: 25 to 66)
performed 19% of procedures (n 529 procedures), and the
low number of remaining procedures (n  155; 5%) was
performed by interventionalists with less training in EMB
sampling who were supervised by an experienced proctor in
this field.
Accordingly, in the 161 RV EMB procedures in ARVC
patients, 66% were performed by 3 interventionalists with
experience in 10 or more biopsy procedures in ARVC
(range 10 to 86). The remaining ARVC biopsy procedures
were performed by interventionalists with less experience in
ARVC but extended expertise in biopsy sampling in other
cohorts. Given that biopsy procedures were performed only
atients
C
RV Diseases/CMP
(Control-1)
HTx
(Control-2) p Value
1) 321 (56) 271 (81)
14 43 15 51 13 0.001
) 321 (11) 2,321 (83)
) 2,472 (17) 10,481 (74)
–12) 7 (4–10) 4 (3–5) 0.001
–3) 1 (0–2) 0 (0–0) 0.001
0 0
0 0
* 1 (0.3)* 2 (0.1) 0.53
.7)* 17 (5.2)* 13 (0.6) 0.001; 0.51*
.6)* 7 (2.2)* 0 0.001; 0.21*
.1)* 10 (3.1)* 13 (0.6) 0.001; 1.0*
0 0
0 0
1 (0.04) 2 (0.02) NS
.5)* 17 (0.7)* 13 (0.1) 0.001; NS*
.08)* 7 (0.3)* 0 0.001; NS*
.4)* 10 (0.4)* 13 (0.1) 0.01; NS*
mparison: arrhythmogenic right ventricular cardiomyopathy (ARVC)
quiring pericardiocentesis/drainage due to hemodynamic instability.
rt transplantation; PE pericardial effusion.tudy P
ARV
161 (7
45
161 (6
,305 (9
6 (4
2 (1
0
0
0
6 (3
1 (0
5 (3
0
0
0
6 (0
1 (0
5 (0
roup co
-1). †Reby experienced interventionalists, the event rates of compli-
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1145cations were low in both the overall cohort and the ARVC
subgroup and did not allow a useful correlation with
individual extent of investigator experience.
Semi-quantitative histological analyses of RV biopsy
specimen demonstrated indicative results in 82 of 161
patients (51%) with ARVC according to the current
Figure 1. Example of RV Endomyocardial Biopsy Sampling With Correspond
Right ventricular (RV) angiogram of a patient with arrhythmogenic RV cardiom
left anterior oblique [LAO] 90° projection) (A), and the corresponding position
resulted in histological ﬁndings with ﬁbrofatty replacement of RV myocardium
magniﬁcation.
Table 2. Localization of EMB Sampling in Study Patie
All Pat
Patients 75
Total EMB procedures 2,803 (
Location of RV biopsy sampling
Number of different RV EMB sampling locations 1 (
Septum 2,784 (
Inferior 52 (
Supra-apical 229 (
Free wall 16 (
Outﬂow-tract 245 (
Anterior 97 (
Values are n, n (%), or median (interquartile range). The reported p
(Control-1).Abbreviations as in Table 1.histological criteria (4) (Fig. 1). In 53 of 161 patients
(33%), abnormal histological findings—such as isolated
fatty replacement, mild interstitial fibrosis, or lympho-
cytic cell infiltration, which are considered compatible
but nonspecific for the histological diagnosis of ARVC—
were present. Only in 26 of 161 patients (16%) were no
istopathology
hy depicting regional RV dyskinesia (in a right anterior oblique [RAO] 30° and
the bioptome in the same ﬂuoroscopic projection (B). Sampling in this area
ostic for arrhythmogenic RV cardiomyopathy. (C) Sirius red staining, 10-fold
ARVC
RV Diseases/CMP
(Control-1)
HTx
(Control-2)
p
Value
161 321 271
161 (6) 321 (11) 2,321 (83)
3 (2–4) 2 (1–3) 1 (1–1)
154 (94) 309 (96) 2,321 (100) 0.805
26 (16) 26 (8) 0 0.008
111 (69) 118 (37) 0 0.01
7 (4) 9 (3) 0 0.422
106 (66) 139 (43) 0 0.01
46 (29) 51 (16) 0 0.01
efer to the comparison of the ARVC group versus RV diseases/CMPing H
yopat
ing of
diagnnts
ients
3
100)
1–1)
99)
2)
8)
1)
9)
4)
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1146histological abnormalities detectable, indicating a sam-
pling error due to several potential reasons (i.e., missed
area, minor disease expression, non-subendocardial dis-
ease manifestation not accessible for RV EMB). These
data demonstrate a high diagnostic yield and efficacy of
target-directed RV biopsy sampling (including RV free
wall and predilection areas) in comparison with conven-
tional RV septal sampling in patients with ARVC.
Major procedure-related complications of EMB. There were
no procedure-related deaths or sustained ventricular tachy-
arrhythmias requiring intervention. A transient complete
AV block occurred in 3 patients (Table 1): in 2 HTx
patients it resolved spontaneously; 1 control-1 patient with
the final diagnosis of hypertrophic cardiomyopathy required
temporary cardiac pacing due to hemodynamic relevant
bradycardia. After recovery of conduction, the transient
pacemaker lead was removed at the end of the invasive
procedure before the patient was referred to the intermedi-
ate care unit. No further episodes of conduction abnormal-
ities or AV block occurred during the in-hospital monitor-
ing phase or during a 3-month follow-up.
Cardiac perforation with hemodynamic relevant tam-
ponade necessitating immediate pericardiocentesis oc-
curred in 8 patients (Table 1). Among these were 1
patient with ARVC and 7 control-1 patients. No
control-2 patient experienced cardiac tamponade. Peri-
cardiocentesis was performed with a standard technique
with subxiphoidal percutaneous access and insertion of a
5-F pigtail catheter into the pericardial space for drain-
age. In all patients, the pigtail catheter inserted in the
pericardial space could be removed within 48 h after there
was no additional drainage. No patient required surgical
intervention. However, as a complication of the pericar-
diocentesis, 1 patient (control-1) developed a small sero-
pneumothorax, which resolved spontaneously.
Minor procedure-related complications of EMB. The inci-
dence of minor PE was identical between patients with
ARVC and control-1 (3.1%/EMB procedure; 0.4%/EMB
Table 3. Synopsis of Studies, Including EMB in ARVC Patients Obtained Vi
First Author (Ref. #) Yr of Publication Patients With EMB, n Differe
Menghetti et al. (12) 1996 9
Valente et al. (13) 1998 20
Turrini et al. (14) 1999 38
Calabrese et al. (15) 2000 20
Nava et al. (16) 2000 47
Folino et al. (17) 2002 46
Basso et al. (18) 2006 21
Cho et al. (19) 2007 32
Present study 2011 161
 394
*Defined as death, sustained ventricular tachyarrhythmias, complete AV block, or cardiac tamponaA supra-apical; Ant anterior; FW free wall; Inf inferior; NA not available; OT outflow-tract; Ssamples) (Table 1). In patients after HTx, septal EMB
sampling resulted in a lower rate (0.6%/total control-2 EMB
procedures; 0.1%/total control-2 EMB samples) (Table 1).
Discussion
Target-directed multisite sampling of EMB in patients
with ARVC is perceived to carry a higher risk of major
adverse events, such as myocardial perforation. In our
analysis of 161 EMB procedures, sampling of RV biop-
sies from predilection areas in ARVC patients was not
associated with an increased rate of major complications
in comparison with other diseases when performed by
experienced interventionalists following a precise and
dedicated protocol (Online Appendix).
Even though EMB in patients with ARVC were ob-
tained from multiple RV sites, including the RV free wall
(Table 2), only 1 hemodynamic relevant tamponade requir-
ing immediate pericardiocentesis occurred (0.6%/total
ARVC EMB procedures; 0.08%/total ARVC EMB sam-
ples) (Table 1). A search of the Medline database (National
Library of Medicine, Bethesda, Maryland) for comparable
studies reporting on endovascular EMB in ARVC (query
terms: “ARVC endomyocardial biopsy” and “ARVD endo-
myocardial biopsy”; prerequisites: English language, 15
atients, published within the last 15 years, and EMB
btained in vivo) identified 8 studies comprising a total of
33 patients (12–19) (Table 3). Information on the number
f RV biopsies (13,14,18,19) and the EMB sampling site
ere available in 4 studies (50%) (14,15,18,19) (Table 3). In
hese, the number of EMB/patient was lower, and EMB
ere sampled only from the RV septum when compared
ith our study (Table 3). Severe adverse events were not
entioned.
The overall incidence of major complications (i.e.,
eath, sustained ventricular tachyarrhythmias, complete
V block, cardiac tamponade) in the present study is low
n  11 patients; 0.4%/total EMB procedures; 0.08%/
ndovascular Access
B Sites, n RV Site Number of EMB Complications*
NA NA NA
Sept NA NA
Sept 98 NA
NA 120 NA
NA NA NA
NA NA NA
Sept 2 1/patient NA
Sept 5–7/patient NA
Sept, Inf, A, FW, OT, Ant 9 5/patient 1 (0.6%)†
iring pericardiocentesis/drainage. †Calculated for total ARVC EMB procedures.a an E
nt EM
NA
1
1
NA
NA
NA
1
1
6
de requept septum; other abbreviations as in Table 1.
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1147total EMB samples) (Table 1). However, when compar-
ing these results with available data from the published
reports (5), one might be aware that these studies are
ased on observations recorded from exclusively septal
MB procedures.
Deckers et al. (20) reported a higher percentage of
definite perforations” (n  3 patients; 0.5% of all proce-
ures) in their survey of 546 diagnostic septal procedures
esulting in the death of 2 of these patients in comparison
ith our findings with no sequelae (0.3%) (Table 1). In a
ecent larger single center study on septal EMB procedural
omplications in patients with suspected or confirmed
yocarditis, the number of complete AV block (n  13;
0.5%/EMB procedures) was higher and the number of
pericardial tamponade (n  2; 0.1%/all EMB procedures)
was slightly lower when compared with ours (Table 1) (21).
Although Yilmaz et al. (22) very recently reported a higher
rate of cardiac tamponade (n  4 of 490 [0.82%]) after
RV-EMB.
The occurrence of a hemodynamically insignificant PE as
a minor complication was comparable between patients with
ARVC and control-1 patients (p  NS) (Table 1) as well
that reported by others (0.7% [21]).
The reason for the low complication rates in the present
study might be based in both the dedicated biopsy protocol
(Online Appendix), which was meticulously followed, and
the experience of the interventionalists who performed the
procedure.
Study limitations. Because this topic is a major issue of
oncern, our analysis specifically assesses the feasibility
nd safety of RV EMB sampling. Data on the semi-
uantitative analyses of the RV specimen in our ARVC
atients underscore that, with a target-directed EMB,
he diagnostic yield of EMB in patients with suspected
RVC can significantly be improved (23–25). Yet this is
eyond the primary scope of this manuscript, and results
f quantitative analyses will be reported in detail
lsewhere.
In the present study, 43 different experienced interven-
ionalists performed the EMB sampling. In ARVC patients
his was predominantly done (86 of 161 EMB procedures
53%]) by 1 investigator (T.W.), which might contribute to
he overall low complication rate; however, 47% of the
rocedures in patients with ARVC were done by different
ardiologists over a period of time.
onclusions
Multisite and target-directed EMB sampling, including the
predilection areas of the RV free wall in patients with
ARVC, is a safe procedure when performed by experienced
interventionalists. The procedure-related complications
were low and comparable to those in other RV diseases.These findings might alter the policy of EMB procedures in
ARVC, thereby potentially improving its diagnostic utility.
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